London Markets: London stocks struggle and pound gives up gains
- ByMarketWatch-
The FTSE 100 was an outperformer on Friday, but only just as Europe's stock markets were deep in the red.
Symbol | Exchange | Currency | ||
|---|---|---|---|---|
| London | GBP | Real-time | ||
| Derived | GBP | Real-time | ||
| London | GBP | Real-time | ||
| London | GBP | Real-time | ||
| BATS Europe | SEK | Delayed | ||
| BATS Europe | GBP | Delayed | ||
| OTC Markets | USD | Delayed | ||
| NASDAQ | USD | Real-time | ||
| Mexico | MXN | Delayed | ||
| Stockholm | SEK | Real-time | ||
| Frankfurt | EUR | Delayed | ||
| Xetra | EUR | Delayed | ||
| TradeGate | EUR | Delayed | ||
| Frankfurt | EUR | Delayed | ||
| Buenos Aires | ARS | Delayed |
The FTSE 100 was an outperformer on Friday, but only just as Europe's stock markets were deep in the red.
According to a real-world study from Malaysia, Sinovac Biotech Ltd's (NASDAQ: SVA) COVID-19 vaccine, CoronaVac, showed effectiveness against serious illness. However, shots...
AstraZeneca Plc (NASDAQ: AZN) has reported high-level results from the PROpel Phase 3 trial of Lynparza (olaparib) in metastatic castration-resistant prostate cancer (mCRPC).The...
Europeans Vaccinated With AstraZeneca Should Be Able To Enter US, Says EUAuthored by Lorenz Duschamps via The Epoch Times,People who have received two doses of...
Los Angeles, USA, Sept. 14, 2021 (GLOBE NEWSWIRE) -- Ovarian Cancer Clinical Trials | A Drug Pipeline Analysis Report 2021 | DelveInsightAround 100+ key companies are...
It’s a pretty flat though mildly positive start to trade in Europe again after a decent handover from Asia, whilst Wall Street again registered fresh all-time highs. The S&P 500...
Type | 5 Min | 15 Min | Hourly | Daily | Monthly |
|---|---|---|---|---|---|
| Moving Averages | Strong Sell | Neutral | Buy | Strong Buy | Strong Buy |
| Technical Indicators | Strong Sell | Strong Sell | Strong Buy | Strong Buy | Strong Buy |
| Summary | Strong Sell | Sell | Strong Buy | Strong Buy | Strong Buy |
Name | Last | High | Low | Chg. | Chg. % | Vol. | Time | ||
|---|---|---|---|---|---|---|---|---|---|
| 1,867.80 | 1,890.20 | 1,861.00 | -24.00 | -1.27% | 3.46M | London | |||
| 160.00 | 170.00 | 160.00 | -35.00 | -17.86% | 343.06K | London | |||
| 1.12 | 1.42 | 1.42 | -0.25 | -18.18% | 4.06M | London | |||
| 0.02 | 0.00 | 0.00 | -0.00 | -14.29% | 132.84M | Aquis Exchange | |||
| 10.00 | 10.00 | 7.70 | +2.00 | +25.00% | 103.58K | London | |||
| 1,628.50 | 1,639.50 | 1,624.00 | -16.50 | -1.00% | 2.59M | London | |||
| 1,847.00 | 1,847.00 | 1,845.00 | 0.00 | 0.00% | 263.64K | London | |||
| 137.40 | 139.50 | 106.40 | +28.90 | +26.64% | 10.61M | London | |||
| 196.00 | 196.00 | 196.00 | -10.00 | -4.82% | 49.78K | London | |||
| 680.60 | 685.40 | 644.80 | +26.80 | +4.10% | 5.89M | London | |||
| 1,140.00 | 1,148.00 | 1,130.00 | +9.50 | +0.84% | 513.49K | London | |||
| 2,658.00 | 2,669.00 | 2,651.50 | -12.5 | -0.47% | 2.32M | London | |||
| 320.20 | 321.20 | 315.30 | +2.45 | +0.77% | 36.72M | London | |||
| 919.40 | 932.50 | 918.20 | -15.50 | -1.66% | 6.69M | London | |||
| 15.85 | 17.45 | 15.45 | -0.52 | -3.21% | 15.44M | London |
AstraZeneca PLC is a biopharmaceutical company. It focuses on discovery and development of products, which are then manufactured, marketed and sold. It focuses on three main therapy areas: Oncology, Cardiovascular, Renal & Metabolic (CVRM) and Respiratory, while selectively pursuing therapies in Autoimmunity, Infection and Neuroscience. In CVRM, it is expanding its portfolio into the cardiovascular-renal area with roxadustat, as well as investing to explore the benefits of its SGLT2 and GLP-1 franchises in chronic kidney disease (CKD) and heart failure (HF). It has approximately 38 projects in Phase I, including 26 new molecular entities (NMEs), and 12 oncology combination projects. It has approximately 43 projects in Phase II, including 25 NMEs; six additional indications for projects that have reached phase II, and 12 oncology combination projects. It has approximately 22 projects in late-stage development, either in Phase III/pivotal Phase II studies or under regulatory review.